Works matching DE "OLAPARIB"

Results: 214

Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14568-0

By:

Sha, Xiaowei;
Li, Jiaqian;
Fang, Yunlong;
Feng, Jingjie;
Feng, Yasong;
Wang, Jing;
Si, Yang;
Li, Feng;
Cheng, Shan;
Ding, Wei

Publication type:

Article

GR.5 Identification of molecular biomarkers of response to combinatorial PARP inhibition and immune checkpoint blockade in IDH-Mutant Gliomas.

Published in:

2025

By:

Ellenbogen, Y;
Wang, K;
Patil, V;
Landry, A;
Liu, J;
Ajisebutu, A;
Yefet, L;
Gui, C;
Nassiri, F;
Chen, E;
Zadeh, G

Publication type:

Abstract

TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer.

Published in:

Communications Biology, 2025, v. 8, n. 1, p. 1, doi. 10.1038/s42003-025-08444-7

By:

Qi, Gonghua;
Ma, Hanlin;
Chen, Jingying;
Gai, Panpan;
Teng, Kai

Publication type:

Article

A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer.

Published in:

NPJ Precision Oncology, 2025, v. 9, n. 1, p. 1, doi. 10.1038/s41698-025-01009-1

By:

Sadagopan, Narayanan;
Wang, Hongkun;
Yin, Chao;
Weinberg, Benjamin Adam;
Noel, Marcus Smith;
Mukherji, Reetu;
Geng, Xue;
Marshall, John Lindsay;
He, Aiwu Ruth

Publication type:

Article

Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.

Published in:

Journal of Obstetrics & Gynaecology Research, 2019, v. 45, n. 3, p. 743, doi. 10.1111/jog.13851

By:

Sakamoto, Ikuko;
Hirotsu, Yosuke;
Nakagomi, Hiroshi;
Ikegami, Atsushi;
Teramoto, Katsuhiro;
Omata, Masao

Publication type:

Article

Olaparib Triggers Mitochondrial Fission Through the CDK5/Drp‐1 Signaling Pathway in Ovarian Cancer Cells.

Published in:

Journal of Biochemical & Molecular Toxicology, 2025, v. 39, n. 6, p. 1, doi. 10.1002/jbt.70273

By:

Gao, Xun;
Yin, Qinghua;
Wang, Zhilian

Publication type:

Article

Use of Olaparib in the Management of Metastatic Parathyroid Carcinoma With BRCA1 Mutation.

Published in:

2025

By:

Woodfield, David;
Le, Trang;
Prince, Grace;
Lee, Hyun;
Vachhani, Hetal;
Majety, Priyanka

Publication type:

Case Study

Bioinformatics-based identification of key genes for Olaparib resistance in breast cancer: prognostic implications and therapeutic relevance.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02989-z

By:

Shen, Kezhen;
Li, Xiaozhe;
Zhao, Sihan;
Zhang, Xinyu;
Yu, Le;
Li, Jun;
Cai, Lei

Publication type:

Article

Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02048-7

By:

Wang, Zehua;
Pu, Tao;
Miao, Weiwei;
Gao, Yi;
Gao, Jianwen;
Zhang, Xinyan

Publication type:

Article

Commentary: on Diagnostics and treatment of BRCA-associated cancers with olaparib -- expert position statement.

Published in:

Oncology in Clinical Practice (2450-1654), 2024, v. 20, n. 4, p. 309, doi. 10.5603/ocp.100207

By:

Krzakowski, Maciej

Publication type:

Article

Diagnostics and treatment of BRCA-associated cancers with olaparib -- expert position statement.

Published in:

Oncology in Clinical Practice (2450-1654), 2024, v. 20, n. 4, p. 229, doi. 10.5603/ocp.99216

By:

Kowalik, Artur;
Chudecka-Głaz, Anita;
Kufel-Grabowska, Joanna;
Skoneczna, Iwona;
Kubiatowski, Tomasz

Publication type:

Article

SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway.

Published in:

Cell Death Discovery, 2025, v. 11, n. 1, p. 1, doi. 10.1038/s41420-025-02309-y

By:

Teng, Kai;
Ma, Hanlin;
Gai, Panpan;
Zhao, Xuelian;
Qi, Gonghua

Publication type:

Article

The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer.

Published in:

Nowotwory, 2022, v. 72, n. 1, p. 34, doi. 10.5603/NJO.2022.0004

By:

Zubik, Katarzyna;
Talaśka, Julia;
Sigorski, Dawid;
Nawrocki, Sergiusz

Publication type:

Article

Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 11, p. 3839, doi. 10.3390/jcm12113839

By:

Senguttuvan, Rosemary Noel;
Wei, Christina;
Raoof, Mustafa;
Dellinger, Thanh H.;
Wang, Edward Wenge

Publication type:

Article

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer.

Published in:

Diseases, 2025, v. 13, n. 2, p. 51, doi. 10.3390/diseases13020051

By:

Ishida, Hiroaki;
Manrai, Megumi;
Takashima, Akiko;
Egashira, Hiroki;
Nonaka, Mizuki;
Shimada, Hideaki

Publication type:

Article

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.

Published in:

2022

By:

Gong, Lifeng;
Tang, Yu;
Jiang, Li;
Tang, Wei;
Luo, Shengjun

Publication type:

journal article

O19 | DNA damage as a potential target in canine lymphoma treatment: A comparative transcriptomic evaluation of olaparib effects in two lymphoid cell lines.

Published in:: Journal of Veterinary Pharmacology & Therapeutics, 2023, v. 46, p. 37, doi. 10.1111/jvp.13185
Publication type:: Article

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA.

Published in:

Cancer Research & Treatment, 2023, v. 55, n. 3, p. 1048, doi. 10.4143/crt.2022.1529

By:

Jung-Ki Yoon;
Jongseong Ahn;
Sheehyun Kim;
Hwang-Phil Kim;
Jun-kyu Kang;
Duhee Bang;
Yoojoo Lim;
Tae-You Kim

Publication type:

Article

Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Published in:

2024

By:

Freyer, Gilles;
Floquet, Anne;
Tredan, Olivier;
Carrot, Aurore;
Langlois-Jacques, Carole;
Lopez, Jonathan;
Selle, Frédéric;
Abdeddaim, Cyril;
Leary, Alexandra;
Dubot-Poitelon, Coraline;
Fabbro, Michel;
Gladieff, Laurence;
Lamuraglia, Michele

Publication type:

Correction Notice

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.

Published in:

Molecular Medicine Reports, 2021, v. 23, n. 1, p. N.PAG

By:

Collot, Thomas;
Niogret, Julie;
Carnet, Marion;
Chevrier, Sandy;
Humblin, Etienne;
Favier, Laure;
Bengrine-Lefevre, Leila;
Desmoulins, Isabelle;
Arnould, Laurent;
Boidot, Romain

Publication type:

Article

Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation.

Published in:

Case Reports in Oncology, 2023, v. 16, n. 1, p. 1166, doi. 10.1159/000533198

By:

Kröcher, Anke;
Folprecht, Gunnar;
Winzer, Robert;
Sergon, Mildred;
Bornhäuser, Martin;
Kotzerke, Jörg;
Brogsitter, Claudia

Publication type:

Article

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer.

Published in:

Case Reports in Oncology, 2023, v. 16, n. 1, p. 434, doi. 10.1159/000530981

By:

Sekine, Mana;
Terui, Hitoshi;
Fujimura, Taku;
Asano, Yoshihide

Publication type:

Article

Genome destabilization-associated phenotypes arising as a consequence of therapeutic treatment are suppressed by Olaparib.

Published in:

PLoS ONE, 2023, v. 18, n. 1, p. 1, doi. 10.1371/journal.pone.0281168

By:

Suzuki, Mafuka;
Fujimori, Haruka;
Wakatsuki, Kakeru;
Manaka, Yuya;
Asai, Haruka;
Hyodo, Mai;
Matsuno, Yusuke;
Kusumoto-Matsuo, Rika;
Shiroishi, Mitsunori;
Yoshioka, Ken-ichi

Publication type:

Article

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.

Published in:

PLoS ONE, 2022, v. 17, n. 4, p. 1, doi. 10.1371/journal.pone.0267543

By:

Malenge, Marion M.;
Maaland, Astri Fjelde;
Repetto-Llamazares, Ada;
Middleton, Brian;
Nijland, Marcel;
Visser, Lydia;
Patzke, Sebastian;
Heyerdahl, Helen;
Kolstad, Arne;
Stokke, Trond;
Ree, Anne Hansen;
Dahle, Jostein

Publication type:

Article

Efficacy of olaparib combined with dabrafenib and trametinib for a patient with BRAF mutated and ATM deleted metastatic melanoma.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, n. 7, p. e586, doi. 10.1111/jdv.20483

By:

Marguet, Theo;
Mouret, Stéphane;
Belbézier, Aude;
Castillo‐Ferrer, Camila;
Sancey, Lucie;
Porret, Pauline;
Templier, Isabelle;
Hurbin, Amandine;
Frachet, Véronique;
Amini‐Adle, Mona;
Malissen, Nausicaa;
Charles, Julie

Publication type:

Article

LYNPARZA®(olaparib).

Published in:: AUANews, 2021, v. 26, n. 5, p. 2
Publication type:: Article

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.

Published in:

BMC Pulmonary Medicine, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12890-023-02569-3

By:

Ishimoto, Hiroshi;
Sakamoto, Noriho;
Kido, Takashi;
Ozasa, Mutsumi;
Tsutsui, Shin;
Mori, Mayako;
Setoguchi, Daichi;
Takemoto, Shinnosuke;
Obase, Yasushi;
Ishimatsu, Yuji;
Tomonaga, Chiharu;
Matsumoto, Kanako;
Morisaki, Sachiko;
Miura, Kiyonori;
Mukae, Hiroshi

Publication type:

Article

Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03409-9

By:

Li, Huayi;
Peng, Zikun;
Zhu, Jianqing;
Zhao, Weidong;
Huang, Yi;
An, Ruifang;
Zheng, Hong;
Qu, Pengpeng;
Wang, Li;
Zhou, Qi;
Wang, Danbo;
Lou, Ge;
Wang, Jing;
Wang, Ke;
Kong, Beihua;
Xie, Xing;
Yin, Rutie;
Low, John;
Rozita, Abdul Malik;
Sen, Lim Chun

Publication type:

Article

Olaparib.

Published in:: Australian Prescriber, 2017, v. 40, n. 1, p. 37, doi. 10.18773/austprescr.2016.093
Publication type:: Article

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

Published in:

2020

By:

Lorusso, Domenica;
Bologna, Alessandra;
Cecere, Sabrina Chiara;
De Matteis, Elisabetta;
Scandurra, Giusy;
Zamagni, Claudio;
Arcangeli, Valentina;
Artioli, Fabrizio;
Bella, Mariangela;
Blanco, Giusi;
Cardalesi, Cinzia;
Casartelli, Clelia;
De Vivo, Rocco;
Di Napoli, Marilena;
Gisone, Emanuele Baldo;
Lauria, Rossella;
Lissoni, Alberto Andrea;
Loizzi, Vera;
Maccaroni, Elena;
Mangili, Giorgia

Publication type:

journal article

Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report.

Published in:

2024

By:

Berge, M.;
Giraud, J. S.;
De Percin, S.;
Puszkiel, A.;
Thomas-Schoemann, A.;
Blanchet, B.

Publication type:

Case Study

Bidirectional pharmacokinetic drug interactions between olaparib and metformin.

Published in:

Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 1, p. 79, doi. 10.1007/s00280-023-04591-y

By:

Stanisławiak-Rudowicz, Joanna;
Karbownik, Agnieszka;
Szkutnik-Fiedler, Danuta;
Otto, Filip;
Grabowski, Tomasz;
Wolc, Anna;
Grześkowiak, Edmund;
Szałek, Edyta

Publication type:

Article

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 4, p. 325, doi. 10.1007/s00280-023-04514-x

By:

Baum, Joanna;
Zickler, Daniel;
Bolbrinker, Juliane;
Richter, Rolf;
Braicu, Elena Ioana;
Grabowski, Jacek;
Sehouli, Jalid

Publication type:

Article

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib.

Published in:

2022

By:

Botrus, Gehan;
Roe, Denise;
Jameson, Gayle S.;
Junior, Pedro Luiz Serrano Uson;
Korn, Ronald Lee;
Caldwell, Lana;
Bargenquast, Taylor;
Miller, Max;
Borazanci, Erkut Hasan

Publication type:

Case Study

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway.

Published in:

Journal of Pharmaceutical Policy & Practice, 2024, v. 17, n. 1, p. 1, doi. 10.1080/20523211.2024.2351003

By:

Shahzad, Mahnum;
Naci, Huseyin;
Esselen, Katharine M.;
Dottino, Joseph A.;
Wagner, Anita K.

Publication type:

Article

Biguanides in combination with olaparib limits tumorigenesis of drug‐resistant ovarian cancer cells through inhibition of Snail.

Published in:

Cancer Medicine, 2020, v. 9, n. 4, p. 1307, doi. 10.1002/cam4.2738

By:

Wang, Qiong;
López‐Ozuna, Vanessa M.;
Baloch, Tahira;
Bithras, Joanne;
Amin, Oreekha;
Kessous, Roy;
Kogan, Liron;
Laskov, Ido;
Yasmeen, Amber

Publication type:

Article

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.

Published in:

Cancer Medicine, 2018, v. 7, n. 4, p. 1285, doi. 10.1002/cam4.1318

By:

Mao, Yize;
Huang, Xin;
Shuang, Zeyu;
Lin, Guohe;
Wang, Jun;
Duan, Fangting;
Chen, Jianlin;
Li, Shengping

Publication type:

Article

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-78442-y

By:

Rogmans, Christoph;
Dittrich, Jan;
Hamm, Emily;
Weimer, Jörg Paul;
Holthaus, David;
Arnold, Norbert;
Flörkemeier, Inken;
Maass, Nicolai;
Jansen, Peer;
Dempfle, Astrid;
Bauerschlag, Dirk O.;
Hedemann, Nina

Publication type:

Article

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2 MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.

Published in:

Cells (2073-4409), 2024, v. 13, n. 10, p. 867, doi. 10.3390/cells13100867

By:

Biegała, Łukasz;
Kołat, Damian;
Gajek, Arkadiusz;
Płuciennik, Elżbieta;
Marczak, Agnieszka;
Śliwińska, Agnieszka;
Mikula, Michał;
Rogalska, Aneta

Publication type:

Article

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.694793

By:

Gajan, Ambikai;
Sarma, Ashapurna;
Kim, Seongho;
Gurdziel, Katherine;
Wu, Gen Sheng;
Shekhar, Malathy P.

Publication type:

Article

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.686776

By:

Schettini, Francesco;
Corona, Silvia Paola;
Giudici, Fabiola;
Strina, Carla;
Sirico, Marianna;
Bernocchi, Ottavia;
Milani, Manuela;
Ziglioli, Nicoletta;
Aguggini, Sergio;
Azzini, Carlo;
Barbieri, Giuseppina;
Cervoni, Valeria;
Cappelletti, Maria Rosa;
Molteni, Alfredo;
Lazzari, Maria Chiara;
Ferrero, Giuseppina;
Ungari, Marco;
Marasco, Elena;
Bruson, Alice;
Xumerle, Luciano

Publication type:

Article

Olaparib: First Global Approval.

Published in:

2015

By:

Deeks, Emma

Publication type:

Journal Article

Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions.

Published in:

Journal of Cancer, 2024, v. 15, n. 3, p. 699, doi. 10.7150/jca.90371

By:

Meng Dong;
Hongtao Luo;
Ruifeng Liu;
Jinhua Zhang;
Zhen Yang;
Dandan Wang;
Yuhang Wang;
Junru Chen;
Yuhong Ou;
Qiuning Zhang;
Xiaohu Wang

Publication type:

Article

Development and Evaluation of Self-Microemulsifying Drug Delivery System for Improving Oral Absorption of Poorly Water-Soluble Olaparib.

Published in:

Pharmaceutics, 2023, v. 15, n. 6, p. 1669, doi. 10.3390/pharmaceutics15061669

By:

Kim, Yong-Han;
Kim, Seong-Bo;
Choi, Se-Hee;
Nguyen, Thi-Thao-Linh;
Ahn, Sung-Hoon;
Moon, Kyung-Sun;
Cho, Kwan-Hyung;
Sim, Tae-Yong;
Heo, Eun-Ji;
Kim, Sung Tae;
Jung, Hyun-Suk;
Jee, Jun-Pil;
Choi, Han-Gon;
Jang, Dong-Jin

Publication type:

Article

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring.

Published in:

Pharmaceutics, 2023, v. 15, n. 5, p. 1524, doi. 10.3390/pharmaceutics15051524

By:

Canil, Giovanni;
Orleni, Marco;
Posocco, Bianca;
Gagno, Sara;
Bignucolo, Alessia;
Montico, Marcella;
Roncato, Rossana;
Corsetti, Serena;
Bartoletti, Michele;
Toffoli, Giuseppe

Publication type:

Article

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses.

Published in:

Pharmaceutics, 2023, v. 15, n. 2, p. 360, doi. 10.3390/pharmaceutics15020360

By:

Moran, Jennifer;
Mylod, Eimear;
Kane, Laura E.;
Marion, Caroline;
Keenan, Emily;
Mekhaeil, Marianna;
Lysaght, Joanne;
Dev, Kumlesh K.;
O'Sullivan, Jacintha;
Conroy, Melissa J.

Publication type:

Article

Olaparib Conjugates with Selenopheno[3,2- c ]quinolinone Inhibit PARP1 and Reverse ABCB1-Related Multidrug Resistance.

Published in:

Pharmaceutics, 2022, v. 14, n. 12, p. 2571, doi. 10.3390/pharmaceutics14122571

By:

Makrecka-Kuka, Marina;
Vasiljeva, Jelena;
Dimitrijevs, Pavels;
Arsenyan, Pavel

Publication type:

Article

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance.

Published in:

Pharmaceuticals (14248247), 2025, v. 18, n. 4, p. 528, doi. 10.3390/ph18040528

By:

Speranza, Desirèe;
Omero, Fausto;
Cianci, Vincenzo;
Marafioti, Mariapia;
Infurna, Carla;
Carroccio, Patrizia;
Spina, Edoardo;
Barbieri, Maria Antonietta;
Esposito, Emanuela;
Silvestris, Nicola;
Santarpia, Mariacarmela

Publication type:

Article

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.

Published in:

Pharmaceuticals (14248247), 2021, v. 14, n. 8, p. 804, doi. 10.3390/ph14080804

By:

Velev, Maud;
Puszkiel, Alicja;
Blanchet, Benoit;
de Percin, Sixtine;
Delanoy, Nicolas;
Medioni, Jacques;
Gervais, Claire;
Balakirouchenane, David;
Khoudour, Nihel;
Pautier, Patricia;
Leary, Alexandra;
Ajgal, Zahra;
Hirsch, Laure;
Goldwasser, François;
Alexandre, Jerome;
Beinse, Guillaume

Publication type:

Article

Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report.

Published in:

Current Oncology, 2024, v. 31, n. 1, p. 558, doi. 10.3390/curroncol31010039

By:

Lin, Jane;
Welch, Stephen;
Sanatani, Michael;
Ramadan, Sherif

Publication type:

Article